A new study suggests semaglutide drugs like Ozempic, used for type 2 diabetes, may lower the risk of opioid overdose in patients with opioid use disorder. Findings highlight the need for more research into GLP-1 medications.

In a finding that suggests Ozempic and Wegovy have powers that extend beyond weight loss, a new study finds the medications might also lower people's risk of opioid overdose.

People with a history of opioid abuse who took Novo Nordisk A/S’s Ozempic were less likely to overdose, according to a study that adds to a growing body of evidence suggesting it may help manage addiction.

The active ingredient in the popular diabetes and obesity drugs Ozempic and Wegovy could be linked to a drop in opioid overdoses, a study published in JAMA Network Open found. Why it matters: It's the latest evidence that buzzy drugs known as GLP-1s could be used to address psychiatric disorders,

People that are prescribed semaglutide — the active ingredient in Ozempic — as a treatment for type 2 diabetes may have a reduced risk of an opioid overdose, according to a new study published Wednesday in JAMA Network Open.

The results suggest Ozempic could potentially become a new alternative treatment for opioid use disorder, which could help address the ongoing opioid epidemic.